November 4, 2014
Sumitomo Dainippon President Masayo Tada Sumitomo Dainippon Pharma will maintain its numerical targets in its five-year business plan through FY2017 despite the termination of a global PIII study on BBI608, a promising anticancer drug candidate, as a monotherapy for colorectal...read more